Clovis Oncology acquires rights to FAP-targeted radiopharmaceutical programme from 3B Pharmaceuticals

This article was originally published here

The initial focus is on developing a peptide-targeted radionuclide therapy (PTRT) and imaging agent targeting fibroblast activation protein alpha (FAP). FAP is highly expressed in many epithelial cancers,

The post Clovis Oncology acquires rights to FAP-targeted radiopharmaceutical programme from 3B Pharmaceuticals appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply